NCT03725254 is a Phase 2 clinical trial of lymphadenectomy in Colorectal Cancer, sponsored by Fudan University.

Who is sponsoring NCT03725254?

NCT03725254 is sponsored by Fudan University.

What drugs are being tested in NCT03725254?

Interventions in NCT03725254: lymphadenectomy, chemoradiotherapy.

What condition does NCT03725254 study?

NCT03725254 studies Colorectal Cancer, Retroperitoneal Lymph Node Metastasis, Para-aortic Lymph Node Metastasis.

Is NCT03725254 still recruiting?

NCT03725254 is currently status unknown. Last updated 23 January 2019.

Last reviewed 2019-01-23 · How we verify

NCT03725254

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC

Status unknown Phase 2 Last updated 23 January 2019

What this trial tests

Phase 2 trial testing lymphadenectomy in Colorectal Cancer in 180 participants. Status unknown.

Timeline

20 October 2018

Primary endpoint
1 October 2021

1 October 2024

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	180
Start date	20 October 2018
Primary completion	1 October 2021
Estimated completion	1 October 2024
Sites	1 location across China

Drugs / interventions tested

lymphadenectomy
chemoradiotherapy — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Retroperitoneal Lymph Node Metastasis — all drugs for Retroperitoneal Lymph Node Metastasis →
Para-aortic Lymph Node Metastasis — all drugs for Para-aortic Lymph Node Metastasis →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Colorectal Cancer or Retroperitoneal Lymph Node Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to compare the effects of chemoradiation versus radical surgery in treating retro-peritoneal or para-aortic lymph node metastasis in colorectal cancer. By prolonging patients' progression-free survival, local control rate and overall survival, investigators can conclude the best regimen for colorectal cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Retroperitoneal Lymph Node Dissection in Colorectal Cancer with Lymph Node Metastasis: A Systematic Review.
Fadel MG, Ahmed M, Pellino G, Rasheed S, et al · · 2023 · cited 5× · PMID 36672404 · DOI 10.3390/cancers15020455

Verify or expand the search:

Other trials of lymphadenectomy

Trials testing the same drug.

NCT04419935 — Lymphadenectomy in NSCLC With and Without Adjuvant Therapy · unknown
NCT03796819 — Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma · NA · completed
NCT03322826 — Systematic Sampling of Lymph Nodes vs. Lymphadenectomy According to Intraoperative Frozen Pathology for Pulmonary Invasi · NA · unknown
NCT00732563 — Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer · NA · completed
NCT06385912 — Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer · completed

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03725254 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 23 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03725254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing